Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2320 • ACR Convergence 2024
Nailfold Videocapillaroscopy Findings in Patients with Psoriatic Disease: Is There a Distinctive Psoriatic Pattern?
Eduardo Briones-García¹, Tatiana Sofía Rodríguez-Reyna², Eduardo Martin Nares², Guillermo A Guaracha-Basañez³ and Iris Paola García Herrera⁴, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department., Ciudad de México, Distrito Federal, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion “Salvador Zubirán”, Mexico City, Distrito Federal, Mexico, ⁴Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: The utility of nailfold videocapillaroscopy (NVC) in conditions such as systemic sclerosis and primary Raynaud´s phenomenon is well known. Whether patients with psoriatic disease…
Abstract Number: 2337 • ACR Convergence 2024
Patient Characteristics and Outcomes of Emergency Visits in Psoriatic Arthritis: Results from the U.S. Nationwide Emergency Department Sample (NEDS)
Dominique Feterman Jimenez¹, Rachael Stovall¹, Jose Andres Porres Arnaez², Vishwesh Bharadiya³, Jean Liew⁴, Alison Bays¹, Thomason Jenna⁵, Londyn Robinson⁶, Rashmi Dhital⁷ and Namrata Singh⁸, ¹University of Washington, Seattle, WA, ²Universidad Francisco Marroquin, Guatemala, ³AIIMS, New Delhi, India, ⁴Boston University, Boston, MA, ⁵University of Washington, Division of Rheumatology, Seattle, WA, ⁶University of Washington, Durham, NC, ⁷UC San Diego, Brentwood, TN, ⁸University of Washington, Bellevue, WA
Background/Purpose: Compared with the general population, patients with psoriatic arthritis (PsA) have a higher risk of comorbidities and all-cause mortality. They are also at increased…
Abstract Number: 2361 • ACR Convergence 2024
Assessment of Laboratory Parameter Changes in a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Highly Selective TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis
Arthur Kavanaugh¹, Elena Muensterman², Apinya Lertratanakul³, Ting Hong³, Jingjing Chen³, Peter Pothula⁴, Ejim Mark⁵ and Alan Kivitz⁶, ¹University of California San Diego, La Jolla, CA, ²Takeda Development Center Americas, Cambridge, MA, ³Takeda Development Center Americas, Inc., Cambridge, MA, ⁴Takeda Development Center Americas, Inc., Cambridge, ⁵Takeda Development Center Americas Inc., Cambridge, ⁶Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Zasocitinib (TAK-279) is an oral, highly selective, allosteric tyrosine kinase 2 (TYK2) inhibitor that binds with high specificity to the Janus homology 2 domain…
Abstract Number: 2639 • ACR Convergence 2024
Exploring Weight Trends in Psoriatic Arthritis: Unraveling Effects of Drugs
Pankti Mehta¹, Fadi Kharouf², Shangyi Gao³, Dafna Gladman⁴ and Vinod Chandran¹, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ³Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Previous studies have reported weight gain in Psoriatic arthritis (PsA) with biologics like TNF inhibitors (i). In contrast, no significant increase in body weight…
Abstract Number: 0076 • ACR Convergence 2024
Early (3-Month) and Maintained (12-Month) Comparative Effectiveness of 5 Different Classes of Advanced Therapies in a Large Multinational Cohort of Real-World PsA Patients
William Tillett¹, Rieke Alten², Ennio Lubrano³, Khai Jing Ng⁴, Marcus Ngantcha⁵, Inmaculada de la Torre⁴, Dominika Kennedy⁶, Nicola Gullick⁷ and Dennis McGonagle⁸, ¹Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ²Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, ³Vincenzo Tiberio Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy, ⁴Eli Lilly and Company, Madrid, Spain, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Eli Lilly and Company, Indianapolis, ⁷Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, Coventry, United Kingdom, ⁸National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK, Leeds, England, United Kingdom
Background/Purpose: The primary objective was to report persistence at 24 months among patients who initiated a new b/tsDMARD. Secondary endpoints included descriptive and comparative effectiveness…
Abstract Number: 0447 • ACR Convergence 2024
Pregnancy Outcomes in Women Exposed to Guselkumab: Review of Cases Reported to the Manufacturer’s Global Safety Database
Connie Lin¹, Anja Geldhof², Mauricio Ballina³, Hetal Patel⁴ and Hewei Li⁵, ¹Janssen R&D US, Horsham, PA, ²Director Postmarketing Commitments, Leiden, Netherlands, ³Actelion Research & Development, Basel, Switzerland, Gewerbestrasse, Basel-Landschaft, Switzerland, ⁴Pharmaceutical Companies of Johnson & Johnson, Naperville, IL, ⁵Janssen Pharmaceutical, Hopewell Township, NJ
Background/Purpose: Data pertaining to the use of biologics in immunologic diseases are limited on their use during pregnancy. Guselkumab (GUS) is a human IgG1λ mAb…
Abstract Number: 0595 • ACR Convergence 2024
bDMARD Drug Survival in Combination Therapy with Methotrexate in Psoriatic Arthritis: A Systematic Literature Review and Meta-analysis
Sélina HANNA ABDELMASSIH¹, Tiphaine DUJARDIN², Athan BAILLET¹, Philippe GAUDIN¹ and Xavier ROMAND¹, ¹Centre hospitalier universitaire Grenoble-Alpes, Grenoble, France, ²Hôpital Reine Hortense, Aix-les-Bains, France
Background/Purpose: During the last two decades we’ve witnessed the rising use of biologic disease-modifying antirheumatic drugs (bDMARDs) in the treatment of psoriatic arthritis (PsA), leaving…
Abstract Number: 1047 • ACR Convergence 2024
Impact of Treatment Switching on Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus
Jean Park¹, Cliff Rutter², Elisea Avalos-Reyes³, Mary Anderson⁴, Will Cavers⁵, Dorothea Verbrugge⁶ and Kjel Johnson⁷, ¹CVS Health, Hartford, CT, ²CVS Health, Fair Oaks Ranch, TX, ³CVS Health, Highland Village, TX, ⁴CVS Health, Irving, TX, ⁵CVS Health, Palm Beach Gardens, ⁶CVS Health, Salt Lake City, ⁷CVS Health, Tampa
Background/Purpose: Switching treatment from conventional to biologic disease-modifying antirheumatic drugs (DMARDs) is a common practice for managing autoimmune diseases such as rheumatoid arthritis (RA), psoriatic…
Abstract Number: 1449 • ACR Convergence 2024
Evaluating Spine Structural Damage on a Single CT in Patients with Ankylosing Spondylitis, and According to the Presence of Skin Psoriasis
Andrea MENNINI¹, Damien Loeuille², Isabelle Chary-Valckenaere³, Caroline Morizot⁴ and Marie LAFFAIRE¹, ¹CHRU Nancy, Nancy, France, ²Phd, Nancy Vandoeuvre, Lorraine, France, ³Nancy University Hospital, Vandœuvre-lès-Nancy, Lorraine, France, ⁴Nancy University hospital, Nancy, France
Background/Purpose: To compare, on Thoraco-Abdomino-Pelvic (TAP) computed tomography (CT), structural spinal involvement of the dorsal and lumbar segments in ankylosing spondylitis with (AS-Pso) and without…
Abstract Number: 1474 • ACR Convergence 2024
Efficacy of Guselkumab in Bionaive Psoriatic Arthritis Patients with Severe Disease Activity: Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Christopher Ritchlin¹, Ennio Lubrano², Maria Sole Chimenti³, Evan Leibowitz⁴, Mohamed Sharaf⁵, Oyediran Adelakun⁶, Emmanouil Rampakakis⁷, Francois Nantel⁸, Frederic Lavie⁹ and Atul Deodhar¹⁰, ¹Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ²Vincenzo Tiberio Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy, ³Rheumatology, Allergology and Clinical Immunology, System Medicine Department, University of Rome Tor Vergata, Rome, Italy, ⁴Immunology, Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, ⁶Janssen Research & Development, LLC, Titusville, NJ, ⁷McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ⁸Nantel Medsci Consult, Montreal, QC, Canada, ⁹Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ¹⁰Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: In previous DISCOVER (D)1 and 2 analyses, the fully human IL-23p19-subunit inhibitor guselkumab (GUS) was associated with robust and sustained improvement in PsA signs/symptoms…
Abstract Number: 1985 • ACR Convergence 2024
Underlying Autoimmune Disease Has Not Limited Immune Checkpoint Inhibitor Use or Increased Mortality Risk During Cancer Treatment of US Veterans
Madeline O’Sullivan¹, grant Cannon², Sauer brian³, Jorge Rojas⁴, Gary Kunkel⁵, Jessica A Walsh⁶, Punyasha Roul⁷, shardool Patel¹, Joshua Baker⁸, Bryant England⁹ and Tawnie Braaten¹, ¹University of Utah, Salt Lake City, UT, ²University of Utah and Salt Lake City VA, Salt Lake City, UT, ³Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁴Seattle VA, Mexico, Mexico, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁷UNMC, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA, ⁹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Immune checkpoint inhibitors (ICIs) can cause a variety of immune-related adverse events (irAEs) affecting multiple organ systems, and patients with pre-existing autoimmune disease (AID)…
Abstract Number: 2321 • ACR Convergence 2024
Prevalence and Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease
Nahia Plaza-Aulestia¹, Oihane Ibarguengoitia-Barrena², Blanca Sampedro-Andrada³, Cristina San Juan-Lopez³, Victoria Morillo-Montañes⁴, Irati Urionaguena⁵, Itziar Calvo⁶, David Montero Seisdedos⁷, Lucia Vega-Alvarez², Jose Francisco Garcia Llorente² and Nuria Vegas Revenga⁸, ¹Rheumatology Division, Galdakao-Usansolo University Hospital, Galdakao, Spain, ²Rheumatology Division, Galdakao-Usansolo University Hospital, Bilbao, Spain, ³Digestive Division, Galdakao-Usansolo University Hospital, Galdakao, Spain, ⁴Dermatology Division, Galdakao-Usansolo University Hospital, Galdakao, ⁵Rheumatology Division, Galdakao-Usansolo University Hospital, GERNIKA-LUMO, Spain, ⁶Hospital Universitario de Basurto, Bilbao, Spain, ⁷Galdakao-Usansolo University Hospital, Bilbao, Spain, ⁸Hospital Galdakao- Usansolo, Galdakao, Spain
Background/Purpose: Patients with psoriatic disease (PsD) [psoriasis (PsO) and psoriatic arthritis (PsA)] are at greater risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD) compared…
Abstract Number: 2338 • ACR Convergence 2024
TNF Inhibitor Therapy Increases Absolute Lymphocyte Count Which Is Associated with Lower Mortality in Patients with Psoriatic Arthritis
Lenche Kostadinova¹, Brigid Wilson², Hinnah Siddiqui², Sara Behrens³, Angela Gupta⁴, Megan O'Mara³, Vicky Nahra⁵, Mahesha Makandura⁶, Shahdi Malakooti⁷, Maya Mattar⁸, David A Zidar¹ and Donald D Anthony⁹, ¹Louis Stokes VA Medical Center, cleveland, ²VA Northeast Ohio Healthcare System, Cleveland, ³CWRU, Cleveland, ⁴Brigham and Women's Faulkner Hospital, Rheumatology Center, Jamaica Plain, ⁵University Hospitals Cleveland Medical Center, Cleveland, ⁶Henri Ford Medical Center, Detroit, ⁷MetroHealth at Case Western Reserve University, Cleveland, ⁸Louis Stokes VA medical Center, Mayfield Heights, OH, ⁹Louis Stokes VA Medical Center/Metro Health, Cleveland
Background/Purpose: Pathogenic inflammation in psoriatic arthritis (PsA) includes TNF pathway engagement, and this is associated with morbidity. Recently, we observed lower absolute lymphocyte count (ALC)…
Abstract Number: 2365 • ACR Convergence 2024
Benefits of Achieving Early versus Late Clinical Response After Treatment with Biologic and Targeted Synthetic DMARDs Among Patients with PsA in the CorEvitas PsA/Spondyloarthritis Registry
Philip Mease¹, Xiaolan Ye², Christopher Saffore³, Thomas Iyile⁴, Priscila Magalhaes Reis Nakasato⁵, Taylor Blachley⁶, Paul R. Lakin⁶, Nicole Middaugh⁶ and Alexis Ogdie⁷, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc., waukegan, IL, ⁴AbbVie Inc., hyattsville, MD, ⁵AbbVie Inc., Randolph, NJ, ⁶CorEvitas, LLC, Waltham, MA, ⁷Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Treatment for psoriatic arthritis (PsA) often involves biologic and targeted synthetic DMARDs (b/tsDMARDs). Existing research suggests that starting treatment with b/tsDMARDs early may lead…
Abstract Number: 2640 • ACR Convergence 2024
Comparative Safety and Use of Non-conventional Combination Targeted Therapy in Adults with Psoriatic Arthritis
Alexander Wu¹, Arianna Zhang², Yujia Guo¹, Jialing Liu¹, Donghan Yang¹, Lourdes Perez Chada³, Alexis Ogdie⁴, Jose Scher⁵ and Joseph Merola⁶, ¹University of Texas Southwestern Medical Center, Dallas, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Wayland, MA, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵New York University School of Medicine, New York, NY, ⁶UT Southwestern Medical Center, Newton, MA
Background/Purpose: Psoriatic arthritis is a chronic systemic inflammatory disorder with significant impacts on health and life quality. Achieving good disease control in psoriatic arthritis (PsA)…

« Previous Page
1
…
3
4
5
6
7
…
81
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].